OXT and post-traumatic stress disorder: As administering the clinician-administered PTSD scale (CAPS) to (a selection of) trauma-exposed individuals is likely not feasible in clinical practice – considering the duration of the interview – other clinically applicable screeners for increased PTSD risk and moderators of intranasal oxytocin effects on PTSD symptom development should be assessed before intranasal oxytocin administration for the prevention of PTSD may eventually be feasible in clinical practice.